doi: 10.1097/COH.0b013e3283136cd9.
Novel mechanisms of HIV protease inhibitor resistance
Affiliations
- PMID: 19373034
- DOI: 10.1097/COH.0b013e3283136cd9
Item in Clipboard
Novel mechanisms of HIV protease inhibitor resistance
Curr Opin HIV AIDS.
2008 Nov.
Abstract
Purpose of review: Several alternative mechanisms that cause protease inhibitor resistance have been proposed. A summary of the proposed mechanisms and the status regarding their clinical relevance is given.
Recent findings: At this moment only changes in the cleavage sites of protease (either alone or in the background of protease mutations) have been associated with phenotypic changes in IC50 and virological failure.
Summary: Further studies are necessary to unravel the mechanism, the clinical relevance and potential effect of transmission of these cleavage site changes.
Similar articles
-
HIV protease resistance and viral fitness.Curr Opin HIV AIDS. 2007 Mar;2(2):108-15. doi: 10.1097/COH.0b013e32801682f6. Curr Opin HIV AIDS. 2007. PMID: 19372875
-
Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?Curr Opin HIV AIDS. 2008 Nov;3(6):608-11. doi: 10.1097/COH.0b013e328312972e. Curr Opin HIV AIDS. 2008. PMID: 19373031
-
Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.J Infect Dis. 2009 Sep 1;200(5):698-709. doi: 10.1086/605329. J Infect Dis. 2009. PMID: 19627247
-
Potential impact of early antiretroviral therapy on transmission.Curr Opin HIV AIDS. 2009 May;4(3):215-21. doi: 10.1097/COH.0b013e328329c5ca. Curr Opin HIV AIDS. 2009. PMID: 19532053 Review.
-
Clinical management of HIV-associated lipodystrophy.Curr Opin Lipidol. 2009 Aug;20(4):309-14. doi: 10.1097/MOL.0b013e32832d3bb1. Curr Opin Lipidol. 2009. PMID: 19494771 Review.
Cited by
-
Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure.AIDS Res Ther. 2009 Dec 23;6:30. doi: 10.1186/1742-6405-6-30. AIDS Res Ther. 2009. PMID: 20030841 Free PMC article.
-
Investigating the role of hypothetical protein (AAB33144.1) in HIV-1 virus pathogenicity: A comparative study with FDA-Approved inhibitor compounds through In silico analysis and molecular docking.Heliyon. 2023 Dec 6;10(1):e23183. doi: 10.1016/j.heliyon.2023.e23183. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38163140 Free PMC article.
-
HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.Retrovirology. 2011 Aug 24;8:70. doi: 10.1186/1742-4690-8-70. Retrovirology. 2011. PMID: 21864346 Free PMC article.
-
Long-term treatment outcomes of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who experienced NRTI and NNRTI failure.AIDS Res Ther. 2012 Mar 13;9(1):8. doi: 10.1186/1742-6405-9-8. AIDS Res Ther. 2012. PMID: 22409789 Free PMC article.
-
Modulation of HIV-1 Gag NC/p1 cleavage efficiency affects protease inhibitor resistance and viral replicative capacity.Retrovirology. 2012 Apr 1;9:29. doi: 10.1186/1742-4690-9-29. Retrovirology. 2012. PMID: 22462820 Free PMC article.
LinkOut - more resources
Full Text Sources
Research Materials